Comparison Of The Relative Efficacy And Safety Of Low Molecular Weight Heparin And Unfractionated Heparin For The Treatment Of Venous Thrombosis

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 189-198

  Hirsh, J ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Hospital Treatment; Low Molecular Weight Heparin; Treatment of Venous Out of Thrombosis; Unfractionated Heparin

Indexed keywords

CY 222; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

CLINICAL TRIAL; CONFERENCE PAPER; HOSPITAL PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OUTPATIENT; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VEIN THROMBOSIS;

ADULT; ANTICOAGULANTS; DOUBLE-BLIND METHOD; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; NADROPARIN; PARTIAL THROMBOPLASTIN TIME; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SAFETY; THROMBOEMBOLISM; THROMBOLYTIC THERAPY; THROMBOPHLEBITIS; WARFARIN;

EID: 0029854040     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217298     Document Type: Article

References (20)

1. Frydman A, Bara L, Lcroux Y, Woler M. Chauliac F, Samama M: The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in man given single subcutaneous doses of 20 up to 80 mg. J Clin Pharmacol 1988;28:609-618.
2. Briant L, Caranobe C, Saivin S, Byrou B, Houin G, Boneu B: Unfractionated heparin and CY216. Pharmacokinetics and bioavailabilities of the anti-Factor Xa and Ila. Effects of intravenous and subcutaneous injection in rabbits. Thromb Haemost 1989;61(3):348-353.
3. Bratt G, Tomebohm E, Widlund L, Lockner D: Low molecular weight heparin (KABI 2165, FRAGMIN): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986:42:613-620.
4. Matzsch T, Bergqvist D, Hedner U, Ostergaard P: Effect of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987:57(1):97-101.
5. Bara L, Samama MM: Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1988;Suppl.543:65-72.
6. Bradbrook ID, Magnani HN, Moelker HC, Morrison PG. Robinson J. Rogers HJ, Spector RG, VandintherT, Winjnand H: ORG 10172: a low molecular weight heparinoid anticoagulant with a long half life in man. Br J Clin Pharmacol 1987;23:667-675.
7. Handeland GF, Abidgaard GF, Holm U, Arnesen K-E: Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990;39:107-112.
8. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen K-E, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Loerum F, Scheel B. Sortland O, Vinje B: Subcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16(Suppl 2):30-37.
9. Faivre R, Neuhart E, Kieffer Y, Toulemonde F, Bassand JP, Maurat JP: Subcutaneous administration of a low molecular weight heparin CY222 compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thromb Haemost 1987; 58(Suppl):430.
10. Bratt G, Tornebohm E. Granqvist S, Aberg W, Lockner D: A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep vein thrombosis. Thromb Haemost 1985;54:813-817.
11. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D: Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990;64(4):506-510.
12. Duroux P. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991;65:251-256.
13. Simmoneau G. Charbonnier B, Decousus H et al. Subcutaneous fixed dose of enoxaparin versus intravenous adjusted dose of unfractionated heparin in the treatment of deep venous thrombosis. Arch Intern Med 1993; 153:1541-1546.
14. Prandoni P, Lensing AWA, Buller HR, Carta M. Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445.
15. Albada J, Nieuwenhuis HK, Sixma JJ: Treatment of acute venous thromboembolism with low molecular weight heparin. (Fragmin) Circulation 1989;80:935-940.
16. Lensing AWA, Prins MH, Davidson BL, Hirsh J: Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-607.
17. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA. Elliott G, Lerner RG, Hall J. Sparling T, Bretelli HR, Norton J, Carter CJ, George R. Merli G, Ward J. Mayo W, Roscnbloom D, Brant R: Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982.
18. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W. Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A: A comparison of low molecular weight heparin administered primarily at home with unfractionalted heparin administered in the hospital for proximal deep vein thrombosis. N Eng J Med 1996;334(11):677-681.
19. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, dc Haes H, van den Belt AGM, Sagnard L, D'Azemar P, Buller HR for the TASMAN Study Group: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Eng J Med 1996:334(11):682-687.
20. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla F, Poli T, Tagliaferri A, Dettori AG: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994 1994:72(2): 191-197.